scholarly journals Extrapolation Of A Controversial Subject In Pregnancy And Puerperium: The Influence Of Combined Oral Contraceptive Use Over Body Mass Index And Biliary Symptoms

2012 ◽  
Vol 18 (2) ◽  
pp. 72-76
Author(s):  
Irina Tica ◽  
V.I. Tica ◽  
Claudia Mihailov ◽  
A. Mitroi
Keyword(s):  
Body Mass Index ◽  
Oral Contraceptive ◽  
Body Mass ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
The Body ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Oral Contraceptive Use ◽  
Ultrasound Evaluation

AbstractIntroduction and aim: Because for the majority of women one of the most unwanted effect of combined oral contraceptive use is considered to be weight increasement, our study aim was to find out if there is a correlation between the use of combined oral contraceptives in the present or past and the body mass index in a group of pregnant, puerperal and matching control patients.Material, patients and method:In a prospective cohort (Regional University Hospital - Constanţa), 176 patients were included in 3 groups: pregnant, puerperal and matching non-pregnant women (control). For each patient a chart was considered, with the following parameters, age, height, weight, BMI, type of diet, use of combined oral contraceptives in the present or in the past (more than 6 months), ultrasound evaluation of gallbladder’ content.Conclusion:In our study, the use of combined oral contraceptives was not correlated with a high BMI but it seems to correlate with a higher incidence of biliary dyspeptic symptoms in patients without biliary sludge or stones.

scholarly journals Use of Combined Oral Contraceptives and Headaches

Medicina ◽  
2011 ◽  
Vol 47 (5) ◽  
pp. 36
Author(s):  
Diana Šimonienė ◽  
Virginija Vanagienė ◽  
Birutė Žilaitienė ◽  
Tadas Vanagas
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Sexual Partner ◽  
Odds Ratio ◽  
Contraceptive Use ◽  
Daily Activities ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Oral Contraceptive Use ◽  
Steady Sexual Partner

Objective. The study was designed to examine the certain patterns of combined oral contraceptive use in women of childbearing potential and evaluate the relationship between the use of combined oral contraceptives and headaches, bad habits, type of work, and concomitant diseases. Material and Methods. In total, 194 randomly selected women aged 18 to 40 years who visited a gynecologist for preventive gynecological examination were surveyed. Respondents were categorized as combined oral contraceptive users (n=116; study group) and nonusers (n=78; control group). An anonymous questionnaire developed by the authors of this study and a standardized scale called the Migraine Disability Assessment Scale (MIDAS) were used for the survey. Results. A multivariate logistic regression analysis demonstrated a significantly higher prevalence of combined oral contraceptive use in women older than 20 years (odds ratio, 6.0; 95% CI, 2.6–14), better educated women (odds ratio, 5.7; 95% CI, 2.1–15.2), and women reporting a steady sexual partner (odds ratio, 4.0; 95% CI, 1.5–11.0). Relationship between headaches and use of combined oral contraceptives as well as other factors were analyzed in a group of 178 respondents; the rest 16 respondents reported not having headaches at all. The prevalence of reported minimal-tomild and moderate-to-severe impact of headaches on daily activities did not differ significantly between the study and control groups, women with and without bad habits, and white-collar and bluecollar groups (P>0.05). However, women with concomitant diseases significantly more often reported moderate-to-severe impact on daily activities due to headaches (P<0.01). Differences in impact of headaches on daily activities between women using combined oral contraceptives containing 20 or less μg of ethinylestradiol and 30 or more μg of ethinylestradiol did not differ significantly. Conclusions. The prevalence of combined oral contraceptive use was higher in women older than 20 years, better educated women, and women reporting a steady sexual partner. The impact of headaches on daily activities did not differ significantly between the combined oral contraceptive users and nonusers.

EFFECTS OF ORAL CONTRACEPTIVE USE ON BODY MASS INDEX AND BLOOD PRESSURE AMONG FEMALE VILLAGERS IN NORTH-EAST THAILAND

2003 ◽  
Vol 35 (2) ◽  
pp. 243-261 ◽  
Author(s):  
NOBUKO MURAYAMA ◽  
AYU MATSUNAGA ◽  
LADDA TANGBANLUEKAL ◽  
SUWALEE TANTAWIWAT ◽  
RYUTARO OHTSUKA
Keyword(s):  
Blood Pressure ◽  
Body Mass Index ◽  
Oral Contraceptive ◽  
Body Mass ◽  
Contraceptive Use ◽  
Age Groups ◽  
Sociodemographic Factors ◽  
North East ◽  
Oral Contraceptive Use ◽  
Contraceptive Pills

The use of contraceptives has become prevalent among females in Thailand in the past 20 years, and oral contraceptive use has been suggested to trigger changes in fat intake, energy expenditure, fat metabolism and blood pressure. Based on field investigations of 391 married women aged 20 years or over in Yasothon Province, North-east Thailand, this study aims to elucidate the effects of oral contraceptive use on body mass index (BMI: kg/m2 ) and blood pressure, taking into account reproductive histories and socioeconomic conditions. The proportion of obese (BMI> 25) subjects was high in the age groups 30–39, 40–49 and 50–59, accounting for, respectively, 39·4%, 51·1% and 48·5% of these populations. The proportion of women with hypertension (90/140 mmHg) was 23·7%, 18·5% and 26·2% in the 40–49, 50–59 and 60–69 age groups. Current contraceptive practices in the studied population included sterilization by operation, oral contraception and injection. These methods accounted for 43·0%, 12·8% and 8·2% of the population, respectively. Sociodemographic factors such as reproductive history, years of education and household income were not significantly related to BMI or to blood pressure (ANOVA with age adjustment). In contrast, oral contraceptive users had significantly higher BMIs and diastolic blood pressures (p<0·01, ANOVA with age adjustment). Multiple regression analysis also revealed that oral contraceptive use was a weak but significant contributing factor to both high BMI and blood pressure when sociodemographic factors were taken into account and controlled for statistically. It can thus be concluded that the use of contraceptive pills, which contain oestrogen and progestin and are provided free of charge to Thai women, tend to increase BMI and to elevate blood pressure.

Cardiometabolic and Hemostatic Profiles of Women Carriers of Hemoglobin Variants Using Combined Oral Contraceptives

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4851-4851
Author(s):  
Junia Raquel Dutra Ferreira ◽  
Caroline Conceição Guarda ◽  
Rayra Pereira Santiago ◽  
Luane Rocha ◽  
Jessica SANTOS Ferreira ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
Density Lipoprotein ◽  
Reproductive Age ◽  
Lipoprotein Cholesterol ◽  
Combined Oral Contraceptives ◽  
Combined Oral Contraceptive ◽  
Hemoglobin Variants ◽  
D Dimer

Abstract Introduction: Several studies reported combined contraceptives influence in hemostatic and lipid profile besides the concern about the thromboembolism and cardiovascular risks due to the steroids hormones use. As women with hemoglobin (Hb) variants have a pre-existing inflammatory condition and considering the high frequency of hemoglobin variant worldwide, this study aims to evaluate the association of hematological, lipid, glicemic, inflammatory and hemostatic profiles in women using combined oral contraceptives and carriers of hemoglobin variants. Methods: We performed a cross-sectional study including 591 women in reproductive-age. We investigated their hemoglobin profile and COCs use. Of them, we included 60 women with HbAA, 21 with HbAC, 25 with HbAS and 7 with HbSC profiles, all of them combined oral contraceptives users. Among those combined oral contraceptives nonusers, 9 were HbAC and 19 HbSC. We evaluated fasting serum glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), C-reactive protein (CRP), fibrinogen, D-dimer and hematological profile among the studied groups. This study was conducted in accordance and approved by the Research Ethics Committee of the Fundação Oswaldo Cruz - FIOCRUZ, Brazil; and also with the Helsinki Declaration of 1975, and its revisions. Mann-Whitney U tests were used to compare two groups of values within the same variable. Results: We observed significant differences in some hematological and cardiometabolic parameters in women carriers of different Hb variants and using COCs. We found relevant increases in CRP levels in HbSC and HbAC women that seem to be associated with different types of progestins present in combined oral contraceptives formulations. Also, combined oral contraceptives use seems to be associated with decreased HDL-c levels in HbAC women. Otherwise, D-dimer levels were increased in all women with Hb variants, independently of the contraceptive use. Conclusions: Although combined oral contraceptive remains an important method to prevent unintended pregnancy, our data suggest that contraception in women carriers of Hb variants, including those in heterozygosis, should be carefully evaluated, especially, considering the pre-existent inflammatory and pro-thrombotic conditions that together with combined oral contraceptive use may result in additional health problems, such as cardiovascular and thromboembolic diseases. Disclosures No relevant conflicts of interest to declare.

scholarly journals The risk of breast, cervical, endometrial and ovarian cancer in oral contraceptive users

2010 ◽  
Vol 63 (9-10) ◽  
pp. 657-661 ◽  
Author(s):  
Milena Veljkovic ◽  
Slavimir Veljkovic
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cervical Cancer ◽  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Young Women ◽  
Contraceptive Use ◽  
Epidemiologic Studies ◽  
Oral Contraceptive Use ◽  
Increased Risk

Introduction. Oral contraceptives, mainly combined monophasic pills, are widely used by young women who expect their physicians to prescribe them safe drugs which will not harm their health and which will simplify their life. Numerous epidemiologic studies have been performed to determine the relation between oral contraceptive use and the development of neoplasms. Breast cancer. An increased incidence of breast cancer has occurred simultaneously with the growing use of oral contraceptives. The possibility of a link between the oral contraceptive use and breast cancer has led to intensive research, but studies have provided inconsistent results causing confusion among clinicians. It was noticed that the risk of breast cancer was slightly elevated in current and recent young oral contraceptives users. That finding could be influenced by a detection bias or could be due to the biologic effect of the pills. The absolute number of additional breast cancer cases will be very small because of low baseline incidence of the disease in young women. Oral contraceptives probably promote growth of the already existing cancer, they are probably promoters not initiators of breast cancer. The available data do not provide a conclusive answer that is need. Cervical cancer. Numerous factors may influence the development of cervical cancer. The evidence suggests that current and recent oral contraceptive users have an increased risk of cervical cancer which decline after discontinuation of the application of medication. Oral contraceptives might increase the biological vulnerability of the cervix. Cervical cancer develops slowly over a long time period and can be effectively prevented by periodic cervical screening. Fortunately, oral contraceptives do not mask abnormal cervical citology. Conclusions regarding invasive cervical cancer and oral contraceptive use are not definitive but if there is any increased risk, it is low. Endometrial cancer. In oral contraceptive users the endometrium is almost under the influence of progestin component which suppresses endometrial mitotic activity and its proliferation. Most epidemiologic studies show that oral contraceptives reduce the risk of endometrial cancer and that this protective effect exists many years after the discontinuation of medication. Ovarian cancer. It has been long known that the oral contraceptive use causes protective an ovulation and reduces the risk of ovarian cancer. This powerful reduction is the best demonstrated major benefit of oral contraception. This protection is especially observed in nulliparous and seems to persist for many years after the discontinuation of medication.

The use of oral contraceptives in women over age 35 years

1995 ◽  
Vol 4 (2) ◽  
pp. 115-120
Author(s):  
Robert F Casper ◽  
Selim Senoz ◽  
Avraham Ben-Chetrit
Keyword(s):  
Cardiovascular Disease ◽  
Oral Contraceptive ◽  
Oral Contraceptives ◽  
Contraceptive Use ◽  
Older Woman ◽  
Oral Contraceptive Use ◽  
Increased Risk ◽  
Potential Risks ◽  
Europe Today ◽  
The Impact

Oral contraceptives remain the most widely used form of contraception in North America and Europe today. In spite of the concerns of many women relating to the potential risks of these preparations, recent data have demonstrated that currently available oral contraceptives are safe, with no increased risk of cardiovascular disease or cancer in nonsmoking women. The present review will focus on the impact of oral contraceptive use in the older woman, including a discussion of the noncontraceptive health benefits of oral contraceptives.

scholarly journals Accuracy of Self-Screening for Contraindications to Combined Oral Contraceptive Use

2008 ◽  
Vol 112 (3) ◽  
pp. 572-578 ◽  
Author(s):  
Daniel Grossman ◽  
Leticia Fernandez ◽  
Kristine Hopkins ◽  
Jon Amastae ◽  
Sandra G. Garcia ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Contraceptive Use ◽  
Combined Oral Contraceptive ◽  
Oral Contraceptive Use
Sign in / Sign up

Export Citation Format

Share Document